GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Common Stock

Resverlogix (FRA:RFS) Common Stock : €306.02 Mil (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Common Stock?

Resverlogix's quarterly common stock increased from Jun. 2023 (€307.50 Mil) to Sep. 2023 (€312.63 Mil) but then declined from Sep. 2023 (€312.63 Mil) to Dec. 2023 (€306.02 Mil).

Resverlogix's annual common stock increased from Dec. 2021 (€289.29 Mil) to Dec. 2022 (€312.86 Mil) but then declined from Dec. 2022 (€312.86 Mil) to Dec. 2023 (€306.02 Mil).


Resverlogix Common Stock Historical Data

The historical data trend for Resverlogix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Common Stock Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.57 281.19 289.29 312.86 306.02

Resverlogix Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 334.28 312.86 307.50 312.63 306.02

Resverlogix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Resverlogix (FRA:RFS) Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix (FRA:RFS) Headlines

No Headlines